Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury

Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury

Abbott and Action Pharma A/S announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in ... more

Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury demonstrates positive top-line results

Action Pharma A/S announced positive top-line results for its phase IIb AP214 trial in patients undergoing major cardiac surgery. The study demonstrated that AP214 is safe, reduces kidney injury, and improves long-term (90 days) outcomes on a composite end point (death, dialyses and kidney ... more

Last patient completes last visit in Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery

The final patient has performed the last visit of the study period in Action Pharma’s US and Denmark based phase IIb study. Treatment with AP214 is designed to investigate whether acute kidney injury can be prevented in patients undergoing major cardiac surgery – a serious unmet medical nee ... more

Action Pharma A/S

Action Pharma is a privately owned Danish biotech company. The main strategy of Action Pharma is to develop novel drug candidates targeting melanocortin receptors and bring these to clinical proof of concept for subsequent partnering. The drug candidates are first in class and exploit novel ... more

Abbott completes separation of research-based pharmaceuticals business

Abbott  announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie begins trading independently on the New York Stock Exchange under the symbol "ABBV." "We wish our colleagues at AbbVie c ... more

Abbott's HUMIRA (Adalimumab) Approved in Europe for Severe Active Pediatric Crohn's Disease

Abbott announced that the European Commission has approved HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. With this approval, HUMIRA bec ... more

Abbott to Collaborate with Astellas in CMV Vaccine Trial

Abbott announced that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients.U ... more

Abbott de Mexico, S.A. de C.V.

We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comp ... more

Abbott GmbH & Co. KG

To meet the ever growing needs of modern medicine and combat emerging new diseases, there is a constant demand for improved diagnostic methods, therapeutic approaches and technologies. As a leading manufacturer of health care products, it is Abbott's goal to meet these needs worldwide. In G ... more

Abbott Japan Co., Ltd.

To meet the ever growing needs of modern medicine and combat emerging new diseases, there is a constant demand for improved diagnostic methods, therapeutic approaches and technologies. As a leading manufacturer of health care products, it is Abbott's goal to meet these needs worldwide. In G ... more